Generali Investments Towarzystwo Funduszy Inwestycyjnych (TFI)’s CRISPR Therapeutics CRSP Stock Holding History

Generali Investments Towarzystwo Funduszy Inwestycyjnych (TFI)’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$818K	Hold	15,000	–	–	0.33%	83
2026 Q1	$714K	Sell	15,000 -2,000	-12%	-$105K	0.37%	79
2025 Q4	$891K	Sell	17,000 -1,000	-6%	-$59.9K	0.43%	68
2025 Q3	$1.17M	Sell	18,000 -3,000	-14%	-$172K	0.62%	52
2025 Q2	$1.02M	Hold	21,000	–	–	0.53%	57
2025 Q1	$715K	Buy	21,000 +2,000	+11%	+$84.8K	0.45%	66
2024 Q4	$748K	Buy	19,000 +4,000	+27%	+$189K	0.43%	66
2024 Q3	$705K	Buy	15,000 +1,000	+7%	+$50.7K	0.45%	67
2024 Q2	$756K	Buy	14,000 +4,300	+44%	+$249K	0.49%	61
2024 Q1	$661K	Hold	9,700	–	–	0.46%	66
2023 Q4	$607K	Hold	9,700	–	–	0.5%	63
2023 Q3	$607K	Buy	9,700 +1,700	+21%	+$87.8K	0.5%	63
2023 Q2	$449K	Hold	8,000	–	–	0.39%	71
2023 Q1	$362K	Buy	+8,000	New	+$389K	0.37%	67

Other funds holding CRSP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

Generali Investments Towarzystwo Funduszy Inwestycyjnych (TFI)'s CRSP Position: Q2 2026 in Review

Generali Investments Towarzystwo Funduszy Inwestycyjnych (TFI) held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 15,000 shares worth $818K. The position accounts for 0.33% of the portfolio, ranked #83.

Generali Investments Towarzystwo Funduszy Inwestycyjnych (TFI) first reported a position in CRSP in Q1 2023 and has held it in 14 quarters since. The position peaked at $1.17M in Q3 2025. 371 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Generali Investments Towarzystwo Funduszy Inwestycyjnych (TFI) held 15,000 shares of CRISPR Therapeutics worth $818K as of Q2 2026.
Generali Investments Towarzystwo Funduszy Inwestycyjnych (TFI) left its CRISPR Therapeutics share count unchanged in Q2 2026.
CRISPR Therapeutics made up 0.33% of Generali Investments Towarzystwo Funduszy Inwestycyjnych (TFI)'s portfolio in Q2 2026, its #83 holding.
Generali Investments Towarzystwo Funduszy Inwestycyjnych (TFI) first reported a position in CRISPR Therapeutics in Q1 2023 and has held it in 14 quarters since.
Generali Investments Towarzystwo Funduszy Inwestycyjnych (TFI)'s CRISPR Therapeutics position peaked at $1.17M in Q3 2025.
371 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Generali Investments Towarzystwo Funduszy Inwestycyjnych (TFI)'s 13F filing for Q2 2026, filed 22 Jul 2026.